secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apellis Pharmaceuticals, Inc. (APLS)
CIK:        0001492422
Form:       8-K
Filed at:   2022-01-20T23:59:59+00:00
Accession:  0001193125-22-013866
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apellis enters $300M at-the-market equity offering with Jefferies LLC
---------------------------------------------------------------------

- Apellis may sell up to $300M common stock in at-the-market offerings through Jefferies LLC.
- Jefferies receives commission of up to 3% of gross proceeds for acting as sales agent.
- Prior $150M equity distribution agreement with Citigroup and Jefferies terminated.
- Shares sold under existing automatic shelf registration statement effective Jan 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1492422/000119312522013866/0001193125-22-013866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1492422/000119312522013866/d277809d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-013866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer